|
|
Drugs for Uterine Corpus Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 211)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Busulfan | approved, investigational | Phase 3 | 545 | 55-98-1 | 2478 | 1, 4-Dimethanesulfonoxybutane 1, 4-Dimethylsulfonoxybutane 1, {4-Bis[methanesulfonoxy]butane} 1,4-BUTANEDIOL DIMETHANESULFONATE 1,4-Bis(methanesulfonoxy)butane 1,4-Bis(methanesulfonyloxy)butane 1,4-Bis[methanesulfonoxy]butane 1,4-Butanedi yl dimethanesulfonate 1,4-Butanediol dimethanesulfonate 1,4-Butanediol dimethanesulphonate 1,4-Butanediol dimethylsulfonate 1,4-Butanediol, dimethanesulfonate 1,4-Butanediol, dimethanesulphonate 1,4-Butanediyl dimethanesulfonate 1,4-Di(methylsulfonoxy)butane 1,4-Dimesyloxybutane 1,4-Dimethane sulfonyl oxybutane 1,4-Dimethanesulfonoxybutane 1,4-Dimethanesulfonoxylbutane 1,4-Dimethanesulfonyloxybutane 1,4-Dimethanesulphonyloxybutane 1,4-Dimethylsulfonoxybutane 1,4-Dimethylsulfonyloxybutane 2041 C. B 2041 C. B. 2041 C.B 2041 C.B. 4-((Methylsulfonyl)oxy)butyl methanesulfonate 4-methylsulfonyloxybutyl methanesulfonate 55-98-1 AC-198 AC1L1DRQ AC1Q4GRQ AI3-25012 AKOS003614975 AN 33501 Ambap55-98-1 B1022 B2635_FLUKA B2635_SIGMA BRN 1791786 BSPBio_001920 BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE) Bisulfex Busilvex Busulfan Busulfan (JP15/USP/INN) Busulfan GlaxoSmithKline Brand Busulfan Orphan Brand Busulfan Wellcome Busulfan Wellcome Brand Busulfan [INN:JAN] Busulfano Busulfano [INN-Spanish] Busulfanum Busulfanum [INN-Latin] Busulfex Busulphan Busulphane Butanedioldimethanesulfonate Buzulfan C.B. 2041 C6H14O6S2 CB 2041 CCRIS 418 CHEBI:28901 CHEMBL820 CID2478 CPD000058613 Citosulfan D002066 D00248 DB01008 DivK1c_000847 EINECS 200-250-2 FT-0083567 G.T. 41 GT 2041 GT 41 Glaxo Wellcome Brand of Busulfan GlaxoSmithKline Brand of Busulfan Glyzophrol HMS1920I07 HMS2091O09 HMS502K09 | HSDB 7605 I09-1371 IDI1_000847 InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3 KBio1_000847 KBio2_000512 KBio2_003080 KBio2_005648 KBio3_001420 KBioGR_000698 KBioSS_000512 LS-1358 Leucosulfan MLS001076666 MYLERAN (TN) Mablin Methanesulfonic Methanesulfonic acid, tetram ethylene ester Methanesulfonic acid, tetramethylene ester Mielevcin Mielosan Mielucin Milecitan Mileran Misulban Mitosan Mitostan MolPort-001-783-406 Myeleukon Myeloleukon Myelosan Myelosanum Mylecytan Myleran Myleran Tablets Myleran tablets Myleran, Busulfex, Busulfan Mylerlan NCGC00090905-01 NCGC00090905-02 NCGC00090905-03 NCGC00090905-04 NCGC00090905-05 NCGC00090905-06 NCGC00090905-07 NCI-C01592 NCI60_041640 NCIMech_000192 NINDS_000847 NSC 750 NSC-750 NSC-750sulphabutin NSC750 Orphan Brand of Busulfan Prestwick_989 S1692_Selleck SAM002554887 SMR000058613 SPBio_000253 SPECTRUM1500152 ST50825921 Spectrum2_000067 Spectrum3_000320 Spectrum4_000259 Spectrum5_000928 Spectrum_000092 Sulfabutin Sulfabutin (VAN) Sulphabutin Tetramethylene Dimethane Sulfonate Tetramethylene bis(methanesulfonate) Tetramethylene bis[methanesulfonate] Tetramethylene dimethane sulfonate Tetramethylene {bis[methanesulfonate]} Tetramethylenester Kyseliny Methansulfonove Tetramethylenester kyseliny methansulfonove Tetramethylenester kyseliny methansulfonove [Czech] UNII-G1LN9045DK WLN: WS1&O4OSW1 Wellcome Brand of Busulfan Wellcome, Busulfan X 149 acid, tetramethylene ester alkylating agent: crosslinks guanine residues busulfan butane-1,4-diyl dimethanesulfonate n-Butane-1,3-di(methylsulfonate) |
| | 2 | | Dactinomycin | approved | Phase 3, Phase 2 | 48 | 50-76-0 | 2019, 457193 | (- )-actinomycin d (-)-actinomycin d -pentone 01815_FLUKA 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 50-76-0 A1410_SIGMA A4262_SIGMA A9415_SIGMA AC1L1CQX AC1L9W52 ACT ACT D ACTINOMYCIN D ACTINOMYCIN D AMP ACTINOMYCIN-D ACTO-D ACon0_000471 ACon1_001004 AD AD (VAN) AI3-26374 ActD Actactinomycin A IV Actactinomycin a Iv Actinomycin 11 Cosmegen Actinomycin 11 cosmegen Actinomycin 7 Actinomycin A IV Actinomycin Aiv Actinomycin C (sub1) Actinomycin C(sub1) Actinomycin C1 Actinomycin D Actinomycin D (JP15) Actinomycin D deriv. of 3H-phenoxaocardazine Actinomycin D, sodium deoxyribonucleic acid complex Actinomycin I Actinomycin I (sub1) Actinomycin I(sub 1) Actinomycin I(sub1) Actinomycin I1 Actinomycin IV Actinomycin Iv Actinomycin X 1 Actinomycin X1 Actinomycin iv Actinomycin-(threo-val-pro-sar-meval) Actinomycin-?IV Actinomycin-[threo-val-pro-sar-meval] Actinomycindioic D Acid, Dilactone Actinomycindioic D acid, dilactone Acto-D Antibiotic From Streptomyces Parvullus Antibiotic from Streptomyces parvullus BCBcMAP01_000155 BRD-A42383464-001-02-2 Bio1_000342 Bio1_000831 Bio1_001320 C06770 C1 C62H86N12O16 CBiol_002056 CCRIS 9 CHEBI:123721 CHEBI:27666 CHEMBL1554 CHEMBL427947 CID2019 | CID457193 COSMEGEN (TN) CPD000469227 Chounghwamycin B Cosmegen D Actinomycin D00214 DACTINOMYCIN DB00970 DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA Dactinomicina Dactinomicina [INN-Spanish] Dactinomycin Dactinomycin (USP) Dactinomycin D Dactinomycin [USAN:BAN] Dactinomycine Dactinomycine [INN-French] Dactinomycinum Dactinomycinum [INN-Latin] Dilactone Actinomycin D Acid Dilactone Actinomycindioic D Acid Dilactone actin omycindioic D acid Dilactone actinomycin D acid Dilactone actinomycindioic D acid EINECS 200-063-6 FT-0080366 GNF-PF-1977 HBF 386 HBF 386 Meractinomycin HBF 386 meractinomycin HMS2052O17 HSDB 3220 LMPK14000005 LS-142 Lyovac Cosmegen Lyovac cosmegen MEGxm0_000350 MLS001424196 Meractinomycin MolPort-001-739-741 MolPort-003-925-177 NCGC00025059-02 NCGC00090796-01 NCGC00161622-01 NCGC00161622-02 NCGC00169767-01 NCI-C04682 NCI60_030539 NP-005932 NSC 3053 NSC-3053 NSC191297 NSC3053 Neuro_000003 Oncostatin K Oxamide PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA SAM001246846 SMP1_000005 SMR000469227 UNII-1CC1JFE158 UPCMLD-DP055 UPCMLD-DP055:001 UPCMLD-DP055:002 WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1 X 97 actd actinomycin D actinomycin cl actinomycin x i actinomyein-theo-val-pro-sar-meval dactinomyein d o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine |
| | 3 | | Vincristine | approved, investigational | Phase 3, Phase 2 | 922 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 4 | | Gemcitabine | approved | Phase 3, Phase 2, Phase 1 | 2018 | 95058-81-4 | 60750 | 103882-84-4 122111-03-9 2',2'-DiF-dC 2',2'-Difluoro-2'-deoxycytidine 2',2'-Difluorodeoxycytidine 2'-Deoxy-.beta.-D-2',2'-difluorocytidine 2'-Deoxy-2',2'-difluorocytidine 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one 4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 95058-81-4 AB1004842 AC1L1TUQ C07650 CCRIS 8984 CHEBI:175901 CHEMBL888 CID60750 Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine D02368 DB00441 DDFC DFDC DFdC DFdCyd Folfugem GEO Gamcitabine GemLip Gemcel | Gemcin Gemcitabin Gemcitabina Gemcitabina [INN-Spanish] Gemcitabine Gemcitabine (USAN/INN) Gemcitabine HCl Gemcitabine hydrochloride Gemcitabine stereoisomer Gemcitabinum Gemcitabinum [INN-Latin] Gemtro Gemzar Gemzar (hydrochloride) HMS2089P10 HSDB 7567 Inno-D07001 LS-59139 LY 188011 LY-188011 LY188011 NCGC00168784-01 NChemBio.2007.10-comp25 NSC 613327 NSC613327 TL8005979 UNII-B76N6SBZ8R ZINC18279854 Zefei gemcitabine nchembio.573-comp7 nchembio.90-comp2 | |
| | 5 | | Mechlorethamine | approved | Phase 3, Phase 2, Phase 1 | 397 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 | KBioGR_001448 KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 6 | | Carboplatin | approved | Phase 3, Phase 2, Phase 1 | 2050 | 41575-94-4 | 10339178, 498142, 38904 | (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum /h1-3H2,(H,7,8)(H,9,10) /q 1,1-Cyclobutanedicarboxylate diammine platinum (II) 1,1-Cyclobutanedicarboxylate diammine platinum(II) 2*-1 2*1H2 41575-94-4 70903-55-8 AC-1457 AC1L8I6U Ambap41575-94-4 BSPBio_003145 C 2538 C2043 C2538_SIGMA C6H10N2O4Pt CBDCA CCRIS 3404 CHEBI:31355 CHEMBL1351 CHEMBL288376 CID10339178 CID2567 CID38904 CID426756 CID498142 CID5352133 CID6398587 CID6603770 Carbopaltin Carboplatin Carboplatin (JAN/USP/INN) Carboplatin (USAN) Carboplatin [USAN:INN:BAN:JAN] Carboplatine Carboplatine [French] Carboplatino Carboplatino [Spanish] Carboplatinum Carboplatinum [Latin] Cbdca Cyclobutane-1,1-dicarboxylate D01363 DB00958 Diammine(1,1-cyclobutanedicarboxylato)platinum (II) Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum Diammine-1,1-cyclobutane dicarboxylate platinum II DivK1c_000892 EINECS 255-446-0 EU-0100230 Ercar HMS1921J16 HMS2090M05 HMS2092B22 HMS502M14 HSDB 6957 I14-2390 IDI1_000892 IUPAC: Azane InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6 | JM 8 JM-8 KBio1_000892 KBio2_002009 KBio2_004577 KBio2_007145 KBio3_002645 KBioGR_000713 KBioSS_002009 LS-117689 Lopac-C-2538 Lopac0_000230 MolPort-003-665-501 MolPort-003-845-609 NCGC00015223-01 NCGC00093695-01 NCGC00094961-01 NCGC00094961-02 NCGC00094961-03 NCGC00162099-01 NCGC00162099-02 NCGC00167800-01 NCGC00178242-01 NINDS_000892 NSC 201345 NSC 241240 NSC-241240 NSC201345 NSC241240 Paraplatin Paraplatin (TN) Paraplatin, Carboplatin Paraplatin-AQ Platinum(+2) Cation Platinum(II), (1, 1-cyclobutanedicar Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) Platinum, {diammine[1,1-cyclobut S1215_Selleck SPBio_000716 SPECTRUM1502106 Spectrum2_000898 Spectrum3_001503 Spectrum4_000337 Spectrum5_001094 Spectrum_001529 UNII-BG3F62OND5 azanide carboplatin cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) cis-Diammine(1,1-cyclobutanedicarboxylato) platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diammine(cyclobutanedicarboxylato)platinum II cyclobutane-1,1-dicarboxylic acid diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum nchembio.573-comp10 nchembio773-comp2 nchembio873-comp3 platinum(2+) |
| | 7 | | Cyclophosphamide | approved, investigational | Phase 2, Phase 3 | 2935 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 8 | | Ifosfamide | approved | Phase 3, Phase 2, Phase 1 | 400 | 3778-73-2 | 3690 | (+-)-Ifosfamid (+-)-Ifosphamide (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide (D,L)-Ifosfamide (R,S)-Ifosphamide (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI) 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 3,} 2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 36341-88-5 3778-73-2 84711-20-6 A 4942 AB00513932 AC-2113 AC1L1GHW ASTA Z 4942 Ambap3778-73-2 Asta Z 4942 BPBio1_000865 BRN 0611835 BSPBio_000785 C07047 CAS-3778-73-2 CCRIS 352 CHEBI:5864 CHEMBL1024 CID3690 Cyfos D00343 D007069 DB01181 EINECS 223-237-3 HMS1570H07 HMS2090M12 HMS2093N07 HSDB 7023 Holoxan Holoxan 1000 I-Phosphamide I06-0494 IFEX (TN) Ifex Ifosfamid Ifosfamida Ifosfamida [INN-Spanish] Ifosfamide (JAN/USP/INN) | Ifosfamide Sterile Ifosfamide [USAN:INN:BAN:JAN] Ifosfamidum Ifosfamidum [INN-Latin] Ifosphamide Ifsofamide Iphosphamid Iphosphamid(e) Iphosphamide Iso Endoxan Iso-Endoxan Isoendoxan Isofosfamide Isophosphamide Isosfamide LS-102 LS-99799 MJF 9325 MJF-9325 MLS002154021 Mitoxana Mitoxana, Ifex, Ifosfamide MolPort-003-666-704 N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German] N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine NCGC00016639-01 NCGC00179435-01 NCI-C01638 NCI60_000233 NPFAPI-04 NSC 109,724 NSC 109724 NSC-109,724 NSC-109724 NSC109,724 NSC109724 Naxamide Prestwick0_000833 Prestwick1_000833 Prestwick2_000833 Prestwick3_000833 S1302_Selleck SMR001233348 SPBio_002706 STL058690 UNII-UM20QQM95Y WLN: T6NPOTJ AM2G BO B2G Z 4942 Z-4942 Z4942 ifosfamide isosfamide {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1, | |
| | 9 | | Melphalan | approved | Phase 3 | 729 | 148-82-3 | 4053, 460612 | (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid 148-82-3 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3025 C.B. 3025 c.b 3223-07-2 4-(Bis(2-chloroethyl)amino)-L-phenylalanine 4-14-00-01689 (Beilstein Handbook Reference) 4-[Bis(2-chloroethyl)amino]-L-phenylalanine 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine AC1LA2OE ALKERAN (TN) AY3360000 Alanine Nitrogen Mustard Alkeran AmbotzHAA1563 At-290 BIDD:GT0044 BRD-K87827419-001-02-8 BRN 2816456 BSPBio_002407 C13H18Cl2N2O2 CB 3025 CB-3025 CCRIS 374 CHEBI:165415 CHEBI:28876 CHEMBL852 CID460612 D00369 DivK1c_000653 EINECS 205-726-3 HMS2090B09 HMS2091B16 HMS502A15 HSDB 3234 IDI1_000653 KBio1_000653 KBio2_000877 KBio2_003445 KBio2_006013 KBio3_001627 KBioGR_001284 KBioSS_000877 L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine L-PAM L-Phenylalanine mustard L-Sarcolysin L-Sarcolysine L-Sarkolysin LS-15868 LS-865 | Levofalan Levofolan Levopholan M2011_SIGMA MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)) MLS001333666 MLS002153368 Melfalan Melfalano Melfalano [INN-Spanish] Melphalan (JP15/USP/INN) Melphalan [USAN:INN:BAN:JAN] Melphalanum Melphalanum [INN-Latin] Mephalan MolPort-003-665-535 NCGC00090757-01 NCGC00090757-02 NCGC00090757-03 NCI-C04853 NINDS_000653 NIOSH/AY3360000 NSC 241286 NSC 8806 NSC-8806 NSC241286 NSC8806 P-Di-(2-chloroethyl)amino-L-phenylalanine P-L-Sarcolysin P-N-Bis(2-chloroethyl)amino-L-phenylalanine Phenylalanine mustard Phenylalanine nitrogen mustard Prestwick_1006 RCRA waste no. U150 Rcra waste number U150 SK-15673 SMP2_000174 SMR000058720 SPBio_000287 SPECTRUM1500382 Sarcolysine Sarkolysin Spectrum2_000074 Spectrum3_000684 Spectrum4_000882 Spectrum5_001601 Spectrum_000397 TL8001065 TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN) TRANSGENIC MODEL EVALUATION (MELPHALAN) UNII-Q41OR9510P melphalan p-Bis(beta-chloroethyl)aminophenylalanine p-Di-(2-chloroethyl)amino-L-phenylalanine p-L-Sarcolysin p-L-sarcolysine p-N,N-bis(2-chloroethyl)amino-L-phenylalanine p-N-Bis(2-chloroethyl)amino-L-phenylalanine p-N-Di(chloroethyl)aminophenylalanine p-N-di(chloroethyl)aminophenylala nine phenylalanine nitrogen mu stard |
| | 10 | | Paclitaxel | approved, vet_approved | Phase 3, Phase 2, Phase 1 | 2864 | 33069-62-4 | 36314 | (2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 157069-30-2 33069-62-4 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv. 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv. 7-Epi-Paclitaxel 7-Epi-Taxol 7-Epipaclitaxel 7-Epitaxol 7-epi-Paclitaxel 7-epi-Taxol AB00513812 ABI 007 ABI-007 ABI007 AC-675 AC1L1IOG AC1L1VJI AC1L9AVF ACon1_002231 ANX-513 Abraxane Abraxane (TN) Abraxane I.V. Suspension Abraxis BioScience brand of albumin-bound paclitaxel Ambotz33069-62-4 Anzatax Asotax BIDD:PXR0046 BMS 181339-01 BMS-181339 BMS-181339-01 BPBio1_000320 BRD-A23723433-001-01-2 BRD-A28746609-001-04-0 BRD-K62008436-001-03-1 BSPBio_000290 BSPBio_001152 BSPBio_002614 Bio-0076 Bio1_000362 Bio1_000851 Bio1_001340 Bio2_000416 Bio2_000896 Bristaxol C07394 C466458 C47H51NO14 CCRIS 8143 CHEBI:103439 CHEBI:45863 CHEMBL100910 CHEMBL418410 CHEMBL48 CID36314 CID441276 CID4666 CID6713921 CID6915727 CPD-8718 Capxol D00491 DB01229 DHP-107 DHP-208 DRG-0190 DTS-301 DivK1c_000441 EU-0101201 Ebetaxel EmPAC Epitaxol Genaxol Genetaxyl Genexol Genexol-PM HMS1362J13 HMS1568O12 HMS1792J13 HMS1922K08 HMS1990J13 HMS2090D07 HMS2093K15 HMS501G03 HSDB 6839 I06-0014 IDI1_000441 IDI1_002171 Intaxel KBio1_000441 KBio2_000492 KBio2_002016 KBio2_002509 KBio2_003060 KBio2_004584 KBio2_005077 KBio2_005628 KBio2_007152 KBio2_007645 KBio3_000903 KBio3_000904 KBio3_001834 KBio3_002987 KBioGR_000492 KBioGR_001893 | KBioGR_002509 KBioSS_000492 KBioSS_002016 KBioSS_002517 LMPR0104390001 LS-31070 LipoPac Lopac0_001201 MBT 0206 MEGxp0_001940 MLS000863266 MLS001077297 MLS002154218 MLS002172439 MLS002695976 MPI-5018 Micellar Paclitaxel Mitotax MolPort-001-742-627 MolPort-003-665-783 MolPort-003-932-365 NCGC00024995-02 NCGC00024995-03 NCGC00024995-04 NCGC00024995-05 NCGC00024995-06 NCGC00024995-07 NCGC00164367-01 NCGC00164367-02 NCGC00164367-03 NCI60_000601 NINDS_000441 NK 105 NP-010981 NSC 125973 NSC-125973 NSC125973 NSC358882 Nanotaxel Neuro_000060 Nova-12005 OAS-PAC-100 OncoGel Onxal Onxol Onxol, Taxol, Nov-Onxol, Paclitaxel P1632 Paclical Pacligel Paclitaxel Paclitaxel (JAN/USP) Paclitaxel (JAN/USP/INN) Paclitaxel (Taxol) Paclitaxel [USAN:INN:BAN] Paxceed Paxene Paxoral Plaxicel Praxel Prestwick0_000155 Prestwick1_000155 Prestwick2_000155 Prestwick3_000155 Probes2_000350 QW 8184 S-8184 Paclitaxel Injectable Emulsion S1150_Selleck SDCCGMLS-0066823.P001 SDP-013 SMP1_000228 SMR000394086 SMR000857385 SPBio_000943 SPBio_002229 SPECTRUM1503908 ST50306996 Spectrum2_000872 Spectrum3_001057 Spectrum4_001197 Spectrum5_001491 Spectrum_001536 T 7402 T1912_SIGMA T7191_SIGMA T7402_SIGMA TA1 TAXOL (TN) TAXOL, 10-EPI, TXL TaxAlbin Taxol Taxol A Taxol Konzentrat Taxol.RTM. (Registered Trademark) UNII-P88XT4IS4D UPCMLD-DP108:001 UPCMLD-DP108:002 Vascular Wrap Xorane Yewtaxan abi-007 albumin-bound paclitaxel cMAP_000068 nab-paclitaxel nchembio.188-comp1 nchembio.2007.34-comp9 nchembio.215-comp9 nchembio853-comp6 paclitaxel weekly paclitaxel |
| | 11 | | Cisplatin | approved | Phase 3, Phase 2, Phase 1 | 2770 | 15663-27-1 | 84093, 441203, 2767 | (SP-4-1)-diamminedichloridoplatinum (SP-4-1)-diamminedichloroplatinum (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Abiplatin Biocisplatinum Briplatin CACP CDDP CHEBI:35852 CID441203 CPD0-1392 CPDC CPDD Carboquone Cis Pt II Cis-DDP Cis-Diaminedichloroplatinum Cis-Diamminedichloroplatinum Cismaplat Cisplatine Cisplatino Cisplatinum Cisplatyl Citoplationo DB00515 DDP DDPT Diamminedichloroplatinum | EU-0100918 Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Plastin Platamine Platiblastin Platidiam Platinex Platinol Platinol-AQ Platinoxan Platinum Ammine Chloride Platinum Ammonium Chloride Platinum Diamine Dichloride Randa Trans-DDP Trans-Diaminedichloroplatinum Trans-Diamminedichloroplatinum Trans-Dichlorodiammine Platinum Trans-Platinumdiammine Dichloride cis-DDP cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) nchembio773-comp1 trans-diamminedichloridoplatinum(II) | |
| | 12 | | Etoposide | approved | Phase 3, Phase 2, Phase 1 | 1269 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 13 | | Doxorubicin | approved, investigational | Phase 3, Phase 2, Phase 1 | 1751 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 14 | | Bevacizumab | approved, investigational | Phase 3, Phase 2, Phase 1 | 2020 | 216974-75-3 | | 216974-75-3 Avastin Avastin (TN) Bevacizumab Bevacizumab (genetical recombination) | Bevacizumab (genetical recombination) (JAN) D06409 R-435 anti-VEGF monoclonal antibody antiVEGF bevacizumab | |
| | 15 | | Lenograstim | approved | Phase 3, Phase 2, Phase 1 | 1220 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 16 | | Methylphenidate | approved, investigational | Phase 3 | 375 | 113-45-1 | 4158 | .alpha.-Phenyl-2-piperidineacetic acid methyl ester 113-45-1 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester 2-Piperidineacetic acid, alpha-phenyl-, methyl ester 298-59-9 (hydrochloride) 4311/B Ciba AC1L1HJM C 4311 C07196 CHEBI:6887 CHEMBL796 CID4158 Calocain Centedein Centedrin Centedrine Centredin Concerta D-Methylphenidate HCl D04999 DB00422 DB06701 DEA No. 1724 Daytrana Daytrana (TN) EINECS 204-028-6 Focalin Focalin XR HSDB 3126 L001307 LS-565 METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R) MPH Meridil Metadate Metadate CD Metadate ER MethyPatch Methyl (2-phenyl-2-(2-piperidyl)acetate) Methyl alpha-phenyl-alpha-(2-piperidyl)acetate Methyl alpha-phenyl-alpha-2-piperidinylacetate Methyl phenidate | Methyl phenidyl acetate Methyl phenidylacetate Methylfenidan Methylin Methylin ER Methylofenidan Methylphen Methylphenidan Methylphenidate Methylphenidate (USAN/INN) Methylphenidate HCl Methylphenidate [INN:BAN] Methylphenidate hydrochloride Methylphenidatum Methylphenidatum [INN-Latin] Methylphenidylacetate hydrochloride Methypatch Metilfenidat hydrochloride Metilfenidato Metilfenidato [INN-Spanish] Metilfenidato [Italian] MolPort-001-779-620 NCI-C56280 PMS-Methylphenidate Phenidylate Plimasine Riphenidate Ritalin Ritalin LA Ritalin SR Ritalin hydrochloride Ritalin-SR Ritaline Ritcher Works Ritcher works Tsentedrin UNII-207ZZ9QZ49 alpha-Phenyl-2-piperidineacetic acid methyl ester alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester d-methylphenidate HCl methyl 2-phenyl-2-piperidin-2-ylacetate methyl phenyl(piperidin-2-yl)acetate methylphenidate nchembio.2007.55-comp28 |
| | 17 | | Irinotecan | approved, investigational | Phase 3, Phase 2 | 1123 | 97682-44-5, 100286-90-6 | 60838 | (+)-Irinotecan (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate 1u65 97682-44-5 AC-7469 AC1L1U0Z AC1Q6PGI BRD-K08547377-003-02-4 BSPBio_002346 Bio-0054 Biotecan Biotecan (TN) C16641 C33H38N4O6 CHEBI:105985 CHEMBL481 CID60838 CP0 Campothecin-11 Campto Camptosar | Camptosar, Campto, CPT-11, Irinotecan Camptothecin-11 D08086 DB00762 FT-0083650 HSDB 7607 IRINOTECAN HYDROCHLORIDE Trihydrate IRINOTECAN, CPT-11 Irinotecan (INN) Irinotecan Hcl Irinotecan Hydrochloride Irinotecan Hydrochloride Trihydrate Irinotecan [INN:BAN] Irinotecan hydrochloride Irinotecanum Irinotecanum [INN-Latin] LS-44589 NCI60_005051 NSC728073 S1198_Selleck TL8006026 UNII-7673326042 irinotecan | |
| | 18 | | Methotrexate | approved | Phase 3, Phase 1 | 1551 | 1959-05-2, 59-05-2 | 126941 | 4-amino-10-methylfolic acid 4-amino-N(10)-methylpteroylglutamic acid Abitrexate Amethopterin Amethopterine Antifolan Arbitrexate Emtexate Folex HDMTX L-Amethopterin Ledertrexate MTX Metatrexan | Methopterin Methotextrate Methotrate Methotrexat Methotrexate Sodium Methotrexatum Methylaminopterin Methylaminopterinum Metotrexato Mexate Méthotrexate N-Bismethylpteroylglutamic Acid N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid Rheumatrex Trexall | |
| | 19 | | Topotecan | approved, investigational | Phase 3, Phase 2, Phase 1 | 349 | 119413-54-6, 123948-87-8 | 60700 | (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 123948-87-8 9-Dimethylaminomethyl-10-hydroxycamptothecin 9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin AC-11592 AC1L1TQZ AC1Q6APZ BSPBio_002348 C11158 C23H23N3O5 CCRIS 8163 CHEBI:107501 CHEBI:46035 CHEMBL84 CID60700 D08618 DB01030 HMS2090B20 HSCI1_000228 Hycamptamine Hycamptin Hycamtamine Hycamtin Hycamtin (TN) LS-127395 | MLS000759456 NCGC00178695-01 NCI60_004771 NCIStruc1_001659 NCIStruc2_001796 NChemBio.2007.10-comp24 NSC609699 SK&F-104864-A SKF 104864 SKF-104864-A SKF-S 104864 SMP2_000312 SMP2_000327 SMR000466344 TOPO TOPOTECAN, HYCAMTIN TPT TTC Topotecan (BAN) Topotecan Hcl Topotecan Hydrochloride Topotecan Lactone Topotecan Monohydrochloride, (S)-Isomer Topotecan [INN:BAN] Topotecan lactone Topotecane Topotecane [INN-French] Topotecanum Topotecanum [INN-Latin] UNII-7M7YKX2N15 topotecan |
| | 20 | | Sorafenib | approved, investigational | Phase 3, Phase 2 | 700 | 284461-73-0 | 216239, 406563 | 284461-73-0 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AB1004622 AC-1674 AC1L50CF BAX BAY 43-9006 BAY 43-9006 (free base) BAY 43-9006 tosylate salt BAY 439006 BAY 54-9085 (tosylate salt) BAY-43-0006 BAY-43-9006 BAY-54-9085 BAY43-9006 BRD-K23984367-001-01-8 Bio-0100 CHEBI:47228 CHEBI:50924 CHEMBL1336 CID216239 | D08524 DB00398 DB07438 EN002709 I06-0856 K00597a Kinome_766 LS-186067 LS-187021 LS-187788 MolPort-003-850-270 N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea NCGC00167488-01 NSC-724772 NSC747971 Nexavar STK627350 Sorafenib Sorafenib (INN) Sorafenib [INN] Sorafenib tosylate Sorafenibum UNII-9ZOQ3TZI87 ZINC01493878 nchembio.117-comp17 sorafenib sorafenibum | |
| | 21 | | Morphine | approved, investigational | Phase 3 | 1007 | 57-27-2 | 5288826 | (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (-)-Heroin hydrochloride (-)-Morphine (-)Morphine sulfate (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol (5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol (5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL (7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol (−)-morphine 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol 4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol 47106-99-0 57-27-2 6211-15-0 (sulfate (2:1) (salt) pentahydrate) 64-31-3 64-31-3 (sulfate (2:1) (salt) anhydrous) 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol 8053-16-5 85201-37-2 Apokyn Astramorph PF Avinza BIDD:GT0147 C01516 CCRIS 5762 CHEBI:17303 CHEMBL70 CID5288826 Cube juice D-(-)-Morphine DB00295 DEA No. 9300 DepoDur Depodur Diacetylmorphine hydrochloride Diamorphine hydrochloride Dolcontin Dreamer Dulcontin Duramorph PF Duromorph EINECS 200-320-2 Epimorph HSDB 2134 Hard stuff Heroin hydrochloride Heroine hydrochloride Hocus | Infumorph Kadian LS-91748 M-Eslon M.O.S MOI MORPHINE SULFATE MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE MS Contin MS/L MS/S MSIR Meconium MolPort-003-849-273 Morfina Morfina [Italian] Morphia Morphin Morphin [German] Morphina Morphina [Italian] Morphine Extra-Forte Morphine Forte Morphine H.P Morphine Sulfate Morphine [BAN] Morphinism Morphinum Morphitec Morphium Morpho Moscontin Ms Contin Ms Emma NSC11441 Nepenthe O,O'-Diacetylmorphine hydrochloride OMS Concentrate Oramorph SR Ospalivina RMS RMS Uniserts Rescudose Roxanol Roxanol 100 Roxanol UD SDZ 202-250 SDZ202-250 Statex Statex Drops Statex SR UNII-76I7G6D29C Unkie l-Morphine morfina morphine nchembio.317-comp1 nchembio.64-comp1 |
| | 22 | | Sodium thiosulfate | approved | Phase 3 | 37 | | | | 23 | | Mesna | approved | Phase 3, Phase 1 | 263 | 3375-50-6 | 598 | 2-Mercaptoethane 2-Mercaptoethanesulfonate 2-Mercaptoethanesulfonic acid 2-mercaptoethanesulfonic acid 2-mercaptoethanesulphonic acid 2-mercaptoethylsulfonate 2-sulfanylethylsulfonate | CoM Coenzima M Coenzym M Coenzyme M HS-CoM reduced CoM reduced coenzyme M β-mercaptoethanesulfonic acid | |
| | 24 | | Fentanyl | approved, illicit, investigational, vet_approved | Phase 3 | 821 | 437-38-7 | 3345 | 1-Phenethyl-4-(N-phenylpropionamido)piperidine 1-Phenethyl-4-N-propionylanilinopiperidine 1-phenethyl-4-N-propionylanilinopiperidine 437-38-7 5-22-08-00049 (Beilstein Handbook Reference) 80832-90-2 990-73-8 (citrate) AC1L1FQ2 Actiq BIDD:GT0555 BRN 0494484 CHEBI:119915 CHEMBL596 CID3345 D00320 DB00813 Duragesic Duragesic (TN) Duragesic-100 Duragesic-12 Duragesic-25 Duragesic-50 Duragesic-75 Durogesic EINECS 207-113-6 Fentanest Fentanil Fentanil [DCIT] Fentanila Fentanila [INN-Spanish] Fentanilo Fentanyl Fentanyl (JAN/USAN/INN) Fentanyl CII Fentanyl [INN:BAN] Fentanyl citrate Fentanyl-100 Fentanyl-12 Fentanyl-25 | Fentanyl-50 Fentanyl-75 Fentanylum Fentanylum [INN-Latin] HSDB 3329 IONSYS JNS020QD L001275 LS-124439 Matrifen MolPort-003-847-369 N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-Phenethyl-4-piperidyl)propionanilide N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-phenethyl-4-piperidyl)propionanilide N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide N-Phenethyl-4-(N-propionylanilino)piperidine N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenethyl-4-(N-propionylanilino)piperidine N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide NCGC00168252-01 Nasalfent Oprea1_152073 Oprea1_207148 PDSP1_000860 PDSP2_000846 Pentanyl Phentanyl Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) R 4263 Rapinyl Sentonil Sublimase Sublimaze UNII-UF599785JZ fentanyl | |
| | 25 | | Asparaginase | approved | Phase 3 | 229 | 9015-68-3 | | | Elspar L-asparagine amidohydrolase Putative L-asparaginase precursor |
| | 26 | | Mitoxantrone | approved, investigational | Phase 3 | 272 | 65271-80-9 | 4212 | 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE 1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione 137635-96-2 2fum 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 65271-80-9 70476-82-3 70476-82-3 (hydrochloride) 70711-41-0 70711-41-0 (acetate) 70945-62-9 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI) AB00053716 AC1L1HNY AN-584/42007670 BIDD:PXR0181 BPBio1_000627 BRD-K21680192-300-05-2 BRD-K21680192-300-07-8 BRN 2795126 BSPBio_000569 BSPBio_003160 C11195 C22H28N4O6 CAS-70476-82-3 CCRIS 7604 CHEBI:50729 CHEMBL58 CID4212 D08224 DB01204 DHAD DHAQ DHAQ (*Diacetate salt*) DHAQ HCl Dihydroxyanthraquinone DivK1c_000516 HMS2090D05 IDI1_000516 KBio1_000516 KBio2_002135 KBio2_004703 KBio2_007271 KBio3_002660 KBioGR_001531 KBioSS_002135 LS-20638 Liposome Encapsulated Mitoxantrone (LEM) Lopac-M-6545 Lopac0_000779 MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE MIX | MLS002703044 Misostol Misostol (TN) Mitox Mitoxanthrone Mitoxantron Mitoxantrona Mitoxantrona [INN-Spanish] Mitoxantrone Mitoxantrone (INN) Mitoxantrone (free base) Mitoxantrone 2HCl Mitoxantrone HCl Mitoxantrone [INN] Mitoxantrone dihydrochloride Mitoxantrone hydrochloride Mitoxantronum Mitoxantronum [INN-Latin] Mitozantrone Mitozantrone hydrochloride MolPort-003-849-239 NCGC00015693-01 NCGC00015693-02 NCGC00015693-04 NCGC00162251-01 NCI60_002276 NCI60_002535 NChemBio.2007.10-comp17 NINDS_000516 NSC 279836 NSC-279836 NSC-287836 NSC-299195 NSC-301739 NSC-301739D NSC279836 NSC299195 NSC301739 Neuro_000153 Novantron Novantrone Novantrone(R) (mitoxantrone for injection concentrate) Prestwick0_000385 Prestwick1_000385 Prestwick2_000385 Prestwick3_000385 S2485_Selleck SMP2_000179 SMR001549953 SPBio_000756 SPBio_002490 SR-01000076001 SR-01000076001-7 STK631833 Spectrum2_000908 Spectrum3_001590 Spectrum4_000866 Spectrum5_001205 Spectrum_001655 UNII-BZ114NVM5P VU0244399-2 mitoxantrone |
| | 27 | | Cytarabine | approved, investigational | Phase 3 | 1117 | 147-94-4 | 6253 | (beta-D-Arabinofuranosyl)cytosine (beta-D-arabinofuranosyl)cytosine 1-.beta.-D-arabinofuranosyl-cytosine 1-Arabinofuranosylcytosine 1-beta -D-Arabinofaranosylcytosine 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta -D-Arabinofuranosylcytosine 1-beta-D-Arabinofaranosylcytosine 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta-D-Arabinofuranosyl-Cytosine 1-beta-D-Arabinofuranosylcytosine 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside 1-beta-D-Arabinosyl-Cytosine 1-beta-D-Arabinosylcytosine 147-94-4 1beta -Arabinofuranasylcytosine 1beta -D-Arabinofuranosylcytosine 1beta -D-Arabinosylcytosine 1beta-Arabinofuranasylcytosine 1beta-D-Arabinofuranosylcytosine 1beta-D-Arabinosylcytosine 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS] 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl 30399_FLUKA 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech] 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech] 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one 69-74-9 (hydrochloride) AC-1075 AC1L1M4F AC1Q52OJ AI3-52329 AR3 Alexan Ara-C Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine Ara-Cytidine AraC Arabinocytidine Arabinofuranosylcytosine Arabinosyl Cytosine Arabinosylcytosine Arabitin Aracytidine Aracytin Aracytine Arafcyt BIDD:GT0371 BIDD:PXR0139 BTB15125 Beta-cytosine arabinoside C02961 C1768_SIGMA C2035 C9H13N3O5 CCRIS 913 CHEBI:28680 CHEMBL803 CHX 3311 CID6253 CPD000449317 CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9) Citarabina Citarabina [INN-Spanish] Cytarabin Cytarabina Cytarabine (JP15/USP/INN) Cytarabine [USAN:INN:BAN:JAN] | Cytarabine liposome injection Cytarabinoside Cytarabinum Cytarabinum [INN-Latin] Cytarbel Cytonal Cytosar Cytosar-U Cytosine 1-beta-D-arabinofuranoside Cytosine arabinofuranoside Cytosine arabinose Cytosine arabinoside Cytosine arabinoside (VAN) Cytosine beta-D-arabinofuranoside Cytosine beta-D-arabinofuranoside hydrochloride Cytosine beta-D-arabinoside Cytosine, beta -D-arabinoside Cytosine, beta-D-arabinoside Cytosine-1-beta-D-arabinofuranoside Cytosine-1-beta-D-arabinofuranoside hydrochloride Cytosine-beta -D-arabinofuranoside Cytosine-beta -arabinoside Cytosine-beta-D-arabinofuranoside Cytosine-beta-arabinoside Cytosinearabinoside D00168 DB00987 DepoCyte Depocyt Depocyt (TN) Depocyt (liposomal) Depocyte EINECS 205-705-9 Erpalfa FT-0082880 HMS2051K19 HMS2090A18 HSDB 3049 Intrathecal (injected into the spinal fluid) DepoCyt Intrathecal cytarabine (also known as ara-C) Iretin LS-860 Lopac0_000316 MLS000758310 MLS001066340 MolPort-001-792-509 NCGC00093356-03 NCGC00093356-04 NCGC00093356-05 NCI-C04728 NSC 287459 NSC287459 S1648_Selleck SAM001247012 SMR000449317 SR-01000075773-3 Spongocytidine TL8001048 Tarabine U 19920A U-19,920 U-19920 UNII-04079A1RDZ Udicil ZINC03795098 beta -D-arabinosylcytosine beta -arabinosylcytosine beta -cytosine arabinoside beta-Ara C beta-Ara c beta-Arabinosylcytosine beta-Cytosine arabinoside beta-D-Arabinosylcytosine cytarabine cytarabine liposome injection cytosine-β-D-arabinofuranoside |
| | 28 | | Daunorubicin | approved | Phase 3 | 273 | 20830-81-3 | 30323 | (+)-Daunomycin (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 11006-54-5 11048-29-6 1407-15-4 149541-57-1 20830-81-3 23942-76-9 27576-81-4 28020-80-6 AB00514669 AC1L1JCP AC1Q29OI AI3-52942 Acetyladriamycin Anthracyline Antibiotics From Streptomyces Coeruleorubidus Antibiotics from Streptomyces coeruleorubidus BPBio1_000389 BRD-K43389675-003-02-7 BRN 1445583 BSPBio_000353 C01907 CCRIS 914 CHEBI:41977 CHEMBL178 CID30323 Cerubidin Cerubidine D07776 DAUNORUBICIN HCL DB00694 DM1 Daunamycin Daunarubicinum Dauno-Rubidomycine DaunoXome DaunoXome (TN) Daunoblastin Daunoblastine Daunomycin | Daunomycin Hydrochloride Daunomycin, Hydrochloride Daunorrubicina Daunorubicin Daunorubicin (INN) Daunorubicin (liposomal) Daunorubicin Hcl Daunorubicin Hydrochloride Daunorubicin [INN:BAN] Daunorubicin, Hydrochloride Daunorubicina Daunorubicine Daunorubicinum Daunorubicinum [INN-Latin] Daunoxome EINECS 244-069-7 FI 6339 FI6339 HMS2089H04 HMS2091K06 HSDB 5095 LMPK13050002 LS-187381 LS-997 Leukaemomycin C MolPort-002-533-961 NCGC00024246-05 NCGC00024246-06 NCGC00025173-01 NCI-C04693 NChemBio.2007.10-comp14 NSC 83142 NSC-82151 Ondena Prestwick3_000487 RCRA waste no. U059 RP 13057 Rcra Waste No. U059 Rp 13057 Hydrochloride Rubidomycin Rubidomycin Hydrochloride Rubomycin Rubomycin C Tocris-1467 UNII-ZS7284E0ZP VS-103 daunorubicin nchembio723-comp2 |
| | 29 | | Bortezomib | approved, investigational | Phase 3 | 807 | 179324-69-7 | 387447, 93860 | 179324-69-7 AC1L8TUW Bortezomib Bortezomib (JAN/USAN/INN) CHEBI:287372 CHEBI:41143 CHEMBL325041 CID387447 D03150 DB07475 DPBA FT-0082488 I14-3268 LDP-341 LDP341 LPD 341 LPD-341 | MLN341 MolPort-003-845-298 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide NCI60_029010 NSC-681239 NSC681239 PROSCRIPT BORONIC ACID PS-341 Pyz-Phe-boroLeu S1013_Selleck SBB071337 Velcade Velcade (TN) Velcade, MG-341, PS-341, Bortezomib [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid bortezomib |
| | 30 | | Peginterferon alfa-2b | approved | Phase 3 | 307 | 99210-65-8, 215647-85-1 | | 215647-85-1 D02748 PEG-Intron PegIntron | Peginterferon alfa-2b Peginterferon alfa-2b (INN) Peginterferon alfa-2b (generical recombination) Peginterferon alfa-2b (generical recombination) (JAN) Pegintron (TN) Unitron PEG |
| | 31 | | Histamine | approved, investigational | Phase 3 | 1050 | 75614-87-8, 51-45-6 | 774 | .beta.-Imidazolyl-4-ethylamine 1H-Imidazole-4-ethanamine 1H-Imidazole-5-ethanamine 1avn 1qft 2-(1H-Imidazol-4-yl)ethanamine 2-(1H-Imidazol-4-yl)ethylamine 2-(1H-Imidazol-5-yl)ethanamine 2-(1H-Imidazol-5-yl)ethylamine 2-(1H-imidazol-4-yl)ethan-1-amine 2-(1H-imidazol-5-yl)ethanamine 2-(3H-Imidazol-4-yl)-ethylamine 2-(4-Imidazolyl)ethanamine 2-(4-Imidazolyl)ethylamine 2-(4-imidazolyl)ethylamine 2-Imidazol-4-yl-Ethylamine 2-Imidazol-4-ylethylamine 2-[4-Imidazolyl]ethylamine 4-(2-Aminoethyl)-1H-imidazole 4-(2-Aminoethyl)imidazole 4-Imidazoleethylamine 4-imidazoleethylamine 5-Imidazoleethylamine 5-imidazoleethylamine 51-45-6 53290_FLUKA 64422-25-9 924364-91-0 AC-13185 AC1L19ZT AC1Q54BV AC1Q54BW AKOS000274386 ALBB-005968 BCBcMAP01_000250 BSPBio_001117 BSPBio_002124 Bio1_000487 Bio1_000976 Bio1_001465 Bio2_000389 Bio2_000869 C00388 CCRIS 6535 CHEBI:18295 CHEMBL90 CID774 D08040 DivK1c_000308 EINECS 200-100-6 Eramin Ergamine Ergotidine F411C768-A159-4FC0-A195-291A08BB03AA Free histamine H7125_SIGMA HMS1362G19 HMS1792G19 HMS1990G19 HSDB 3338 HSM Histamine Histamine (DCF) Histamine Base Histamine [USAN] Histamine, Free Base Histaminum | Histaminum (TN) IDI1_000308 IDI1_002144 Imidazole-4-ethylamine Istamina Istamina [Italian] KBio1_000308 KBio2_000457 KBio2_001325 KBio2_003025 KBio2_003893 KBio2_005593 KBio2_006461 KBio3_000853 KBio3_000854 KBio3_001344 KBioGR_000457 KBioGR_001580 KBioSS_000457 KBioSS_001325 L-Histamin base L-Histamine L-histamine L000292 LS-75835 Lopac-H-7250 Lopac0_000595 MLS000069447 MolPort-001-785-597 MolPort-002-042-264 NCGC00015513-01 NCGC00015513-08 NCGC00093371-02 NCGC00093371-03 NCGC00093371-04 NCGC00093371-05 NINDS_000308 NSC 33792 NSC33792 SDCCGMLS-0066601.P001 SMP1_000151 SMR000059091 SPBio_000729 ST073926 STK346752 STOCK5S-55669 Spectrum2_000665 Spectrum3_000452 Spectrum4_000960 Spectrum5_000796 Spectrum_000845 Theramine UNII-820484N8I3 WLN: T5M CNJ D2Z ZERO/004089 [3H]histamine b-Imidazolyl-4-ethylamine beta-Aminoethylglyoxaline beta-Aminoethylimidazole beta-Aminothethylglyoxaline beta-Imidazolyl-4-ethylamine beta-aminoethylglyoxaline beta-aminoethylimidazole beta-aminothethylglyoxaline bmse000744 histamine nchembio.87-comp54 nchembio714-comp1 | |
| | 32 | | Cyproheptadine | approved | Phase 3 | 20 | 129-03-3 | 2913 | 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 129-03-3 4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine 4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine 41354-29-4 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-20-08-00500 (Beilstein Handbook Reference) AC1L1ER8 AKOS004119847 Axoprol BIDD:GT0324 BPBio1_000096 BPBio1_000155 BRD-K28143534-001-01-4 BRD-K28143534-003-03-6 BRN 1685976 BSPBio_000086 Biomol-NT_000131 C06935 CAS-969-33-5 CCRIS 5232 CHEBI:4046 CHEMBL516 CID2913 CYPROHEPTADINE Ciproheptadina Ciproheptadina [INN-Spanish] Ciprovit Ciprovit (TN) Cypoheptadine Cyproheptadiene Cyproheptadin Cyproheptadine | Cyproheptadine (INN) Cyproheptadine Hcl Cyproheptadine [INN:BAN] Cyproheptadinum Cyproheptadinum [INN-Latin] D07765 DB00434 Dibenzosuberonone/Cyproheptadine Dihexazin Dronactin EINECS 204-928-9 Eiproheptadine Glutodina HMS2090P20 HSDB 3048 L001016 LS-114933 Lopac-C-6022 Lopac0_000246 MK 141 MolPort-002-507-777 NCGC00015252-01 NCGC00015252-02 NCGC00015252-03 NCGC00015252-09 NCGC00024293-02 NCGC00024293-04 NCGC00024293-05 Oprea1_498140 PDSP1_001229 PDSP2_001213 Periactin Periactine Periactinol Prestwick0_000103 Prestwick1_000103 Prestwick2_000103 Prestwick3_000103 SPBio_002025 STK802098 Tocris-0996 UNII-2YHB6175DO Viternum nchembio.559-comp10 |
| | 33 | | Nicotinamide | approved, Nutraceutical | Phase 3, Phase 2 | 919 | 98-92-0 | 936 | .beta.-Pyridinecarboxamide 11032-50-1 123574-63-0 1yc5 3 Pyridinecarboxamide 3-Carbamoylpyridine 3-Pyridinecarboxamide 3-Pyridinecarboxylic acid amide 37321-14-5 47865U_SUPELCO 55600-01-6 63748-44-7 72340_FLUKA 72340_SIGMA 72347_FLUKA 78731-47-2 98-92-0 A186B02E-6C70-4E54-9739-79398D439AAA AC-907/25014114 AC1L1ACZ AC1Q4ZFV AI3-02906 Acid amide Amid kyseliny nikotinove Amid kyseliny nikotinove [Czech] Amide PP Aminicotin Amixicotyn Amnicotin Astra Brand of Niacinamide Austrovit PP B 3, Vitamin B3, Vitamin BB_NC-2290 Benicot C00153 C6H6N2O CCRIS 1901 CHEBI:17154 CHEMBL1140 CID936 CPD000058212 D00036 D009536 DB02701 DEA No. 1405 Delonin Amide Delonin amide Dipegyl Dipigyl EINECS 202-713-4 EINECS 234-265-0 Endobion Enduramide Factor pp HMS2052M21 HMS2090B05 HMS2093H03 HSDB 1237 Hansamid I02-1741 I02-2250 InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9 Inovitan PP Jenapharm Brand of Niacinamide Jenapharm, Nicotinsaureamid LS-2051 MLS000069714 Mediatric Merck Brand of Niacinamide MolMap_000061 MolPort-001-783-876 N0078 N0636_SIGMA N2142_SIGMA N3376_SIGMA N5535_SIAL NAM NCGC00093354-03 NCGC00093354-04 NSC 13128 NSC13128 NSC27452 Nandervit-N Niacevit Niacinamide Niacinamide (USP) Niacinamide Astra Brand Niacinamide Jenapharm Brand Niacinamide Merck Brand | Niacinamide Pharmagenix Brand Niacinamide [USAN] Niacinamide, Nicotinic acid amide, Nicotinamide Niacotinamide Niamide Niavit PP Nicamide Nicamina Nicamindon Nicasir Nicobion Nicofort Nicogen Nicomidol Nicosan 2 Nicosylamide Nicota Nicotamide Nicotilamide Nicotililamido Nicotinamid Nicotinamida Nicotinamida [INN-Spanish] Nicotinamide Nicotinamide (JP15/INN) Nicotinamide (Niacinamide) Nicotinamide, niacin, vitamin B3 Nicotinamide-carbonyl-14C Nicotinamidum Nicotinamidum [INN-Latin] Nicotine acid amide Nicotine amide Nicotinic acid amide Nicotinic amide Nicotinsaeureamid Nicotinsaureamid Nicotinsaureamid Jenapharm Nicotinsaureamid [German] Nicotol Nicotylamide Nicotylamidum Nicovel Nicovit Nicovitina Nicovitol Nicozymin Nictoamide Nikasan Nikazan Niko-tamin Nikotinamid Nikotinsaeureamid Nikotinsaeureamid [German] Niocinamide Niozymin PP-Faktor Papulex Pelmin Pelmine Pelonin amide Pharmagenix Brand of Niacinamide Propamine A Pyridine-3-carboxylic acid amide S1899_Selleck SAM001246860 SGCUT00176 SMR000058212 Savacotyl UNII-25X51I8RD4 Vi-Nicotyl Vi-noctyl Vitamin B Vitamin B (VAN) Vitamin B 3 Vitamin B3 amide Vitamin H1 Vitamin PP WLN: T6NJ CVZ Witamina PP ZINC00005878 b-Pyridinecarboxamide beta-Pyridinecarboxamide bmse000281 m-(Aminocarbonyl)pyridine nchembio.154-comp4 nchembio.73-comp6 niacin - Vitamin B3 niacinamide nicotinamide pyridine-3-carboxamide to_000073 vitamin PP |
| | 34 | | Folic Acid | approved, nutraceutical, vet_approved | Phase 3, Phase 2, Phase 1 | 4392 | 59-30-3 | 6037 | (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid 01769_FLUKA 2d0k 33609-88-0 36653-55-1 (mono-potassium salt) 59-30-3 6484-89-5 (mono-hydrochloride salt) AC-11682 AC1L1LNX AI3-26387 AKOS000503224 ARONIS014410 Acfol (Spain) Acide folique Acide folique [INN-French] Acido folico Acido folico [INN-Spanish] Acidum folicum Acidum folicum [INN-Latin] Acifolic Antianemia factor Apo-Folic BIDD:ER0563 BIDD:GT0641 BIF0608 BPBio1_000654 BSPBio_000594 BSPBio_002338 C00504 C20H20N6O6 CAS-59-30-3 CCRIS 666 CHEBI:27470 CHEMBL1622 CID6037 CPD000471860 Cytofol D00070 DB00158 DivK1c_000494 Dosfolat B activ EINECS 200-419-0 F0043 F7876_SIAL F7876_SIGMA F8758_SIGMA F8798_SIAL F8890_SIGMA FOL Facid Factor U Folacid Folacin Folaemin Folaemin [Netherlands] Folan Folasic (Australia) Folate Folbal Folcidin Folcidin (VAN) Folcysteine Foldine Foldine [France] Folettes Foliamin Folic Folic acid Folic acid (JP15/USP/INN) Folic acid (TN) Folic acid [BAN:INN:JAN] Folic acid [INN:BAN:JAN] Folic acid dihydrate Folicet Folicet (TN) Folico Folico (Italy) Folina Folina (Italy) Folipac Folsaeure | Folsan Folsaure Folsav Folvite Folvron Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L HMS1921D20 HMS2092N17 HMS501I16 HSDB 2002 IDI1_000494 InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s Incafolic KBio1_000494 KBio2_001861 KBio2_004429 KBio2_006997 KBio3_001558 KBioGR_002222 KBioSS_001861 Kyselina listova Kyselina listova [Czech] LS-2157 Liver Lactobacillus casei factor MLS001304016 MLS001335861 Millafol Mission prenatal Mittafol MolPort-004-285-551 N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-Pteroyl-L-glutamic acid N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid NCGC00016265-01 NCGC00142391-01 NINDS_000494 NSC 3073 Nifolin Nifolin [Denmark] Novofolacid Novofolacid [Canada] PGA PGA (VAN) Prestwick3_000627 Prestwick_230 PteGlu Pteroyl-L-glutamate Pteroyl-L-glutamic acid Pteroyl-L-monoglutamate Pteroyl-L-monoglutamic acid Pteroylglutamate Pteroylglutamic acid Pteroylmonoglutamate Pteroylmonoglutamic acid SAM002264616 SDCCGMLS-0066738.P001 SMP2_000137 SMR000471860 SPBio_001357 SPECTRUM1502020 Serum Folate Level Spectrum2_001459 Spectrum3_000749 Spectrum4_001751 Spectrum5_000602 Spectrum_001381 UNII-935E97BOY8 Usaf cb-13 Vitamin B11 Vitamin B9 Vitamin Bc Vitamin Be Vitamin M bmse000299 folic acid nchembio.108-comp10 | |
| | 35 | | leucovorin | approved, Nutraceutical | Phase 3, Phase 2, Phase 1 | 3235 | 58-05-9 | 54575, 6560146, 143 | (5-formyl-5,6,7,8-tetrahydropteroyl)glutamate (6R,S)-5-Formyltetrahydrofolate 10-Formyl-7,8-dihydrofolate 10-Formyl-7,8-dihydrofolic acid 5-Formyl-5,6,7,8-tetrahydrofolate 5-Formyl-5,6,7,8-tetrahydrofolic acid 5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid 5-Formyltetrahydrofolate 5-Formyltetrahydrofolic acid 5-Formyltetrahydropteroylglutamate 5-Formyltetrahydropteroylglutamic acid 5-formyltetrahydrofolic acid Acide folinique Calcium citrovorum factor Calcium folinate Citrovorum factor Folinate Folinic acid Folinic acid calcium salt | Folinic acid calcium salt USP27 Folinic acid-SF L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid L-Leucovorin L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid L-leucovorin Leucal Leucovorin calcium Leucovorin folinic acid Leucovorinum Leukovorin Levoleucovorin N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid N5-Formyl-5,6,7,8-tetrahydrofolate N5-Formyl-5,6,7,8-tetrahydrofolic acid N5-Formyl-THF N5-Formyltetrahydrofolate N5-Formyltetrahydrofolic acid Welcovorin Wellcovorin folinate |
| | 36 | | Niacin | approved, investigational, nutraceutical | Phase 3, Phase 2 | 923 | 59-67-6 | 938 | 3-Carboxylpyridine 3-Carboxypyridine 3-Pyridinecarboxylate 3-Pyridinecarboxylic acid 3-Pyridylcarboxylate 3-Pyridylcarboxylic acid 3-carboxypyridine Acide Nicotinique Acido nicotinico Acidum Nicotinicum Akotin Anti-pellagra vitamin Apelagrin Daskil Efacin Enduracin Linic M-Pyridinecarboxylic Acid Niac Niacin Niacine Niacor Nicacid Nicamin Nicangin | Nico-Span Nicobid Nicocap Nicodelmine Nicolar Niconacid Nicosan 3 Nicotinate Nicotinic Acid Nicotinic acid Nicotinipca Nicyl Nikotinsaeure Nyclin P.P. factor PP Factor Pellagra preventive factor Pellagrin Pelonin Pyridine-beta-carboxylic acid Slo-niacin Vitamin B3 Wampocap beta-Pyridinecarboxylic acid pyridine-β-carboxylic acid β-pyridinecarboxylic acid | |
| | 37 | | Dehydroepiandrosterone | approved, nutraceutical | Phase 3 | 95 | 53-43-0 | 9860744 | (+)-Dehydroisoandrosterone (3-beta)-3-Hydroxyandrost-5-en-17-one (3beta)-3-hydroxy-Androst-5-en-17-one (3beta,16alpha)-3,16-dihydroxy-androst-5-en-17-one 17-Chetovis 17-Hormoforin 3-beta-Hydroxy-5-androsten-17-one 3-beta-Hydroxyandrost-5-en-17-one 3b-Hydroxy-D5-androsten-17-one 3b-Hydroxyandrost-5-en-17-one 3beta-Hydroxy-D5-androsten-17-one 3beta-Hydroxyandrost-5-en-17-one 3beta-hydroxy-5-androsten-17-one 3beta-hydroxy-Androst-5-en-17-one 3beta-hydroxyandrost-5-en-17-one 3β-hydroxyandrost-5-en-17-one 5,6-Dehydroisoandrosterone 5,6-Didehydroisoandrosterone 5-Androsten-3-beta-ol-17-one 5-Androsten-3b-ol-17-one 5-Androsten-3beta-ol-17-one 5-DHEA 5-Dehydro-Epiandrosterone | 5-Dehydroepiandrosterone 5-dehydroepiandrosterone Andrestenol Androst-5-ene-3b-ol-17-one Androst-5-ene-3beta-ol-17-one Androsten-3beta-ol-17-one Androstenolone Astenile D5-Androsten-3b-ol-17-one D5-Androsten-3beta-ol-17-one DHEA Deandros Dehydro-epi-androsterone Dehydroandrosterone Dehydroepiandrosterone Dehydroisoandrosterone Diandron Diandrone Hydroxyandrostenone Prasterona Prasterone Prasteronum Prestara Psicosterone trans-Dehydroandrosterone |
| | 38 | | Docetaxel | approved, investigational, Approved May 1996 | Phase 3, Phase 2, Phase 1 | 1967 | 114977-28-5 | 148124, 9877265 | (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 01885_FLUKA 114977-28-5 4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate AC-383 AC1L3WHJ ANX-514 BIND-014 C11231 CHEBI:4672 CHEMBL92 CID148124 D07866 DB01248 Docetaxel Docetaxel (INN) Docetaxel anhydrous Docetaxel, Trihydrate EmDOC | HMS2089K08 InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5 MolPort-003-847-005 N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol N-debenzoyl-N-Boc-10-deacetyl taxol NSC-628503 PSMA-targeted docetaxel nanoparticle RP-56976 SDP-014 TXL Taxotere Taxotere (TN) Taxotere(R) XRP-6976L docetaxel docetaxel 114977-28-5 nchembio.188-comp8 nchembio.2007.34-comp7 nchembio.573-comp11 nchembio853-comp8 |
| | 39 | | Doxil | Approved June 1999 | Phase 3, Phase 2, Phase 1 | 1751 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 40 | | Camptothecin | experimental | Phase 3, Phase 2, Phase 1 | 714 | 7689-03-4 | | (+)-camptothecin (+)-camptothecine (s)-(+)-camptothecin | (s)-camptothecin 20(S)-Camptothecin 21,22-Secocamptothecin-21-oic acid lactone Camptothecine D-camptothecin |
| | 41 | | Nucleic Acid Synthesis Inhibitors | | Phase 3, Phase 2, Phase 1 | 4962 | | | | 42 | | Anti-Infective Agents | | Phase 3, Phase 2, Phase 1 | 22062 | | | | 43 | | Liver Extracts | | Phase 3, Phase 2, Phase 1 | 4067 | | | | 44 | | Antiviral Agents | | Phase 3, Phase 2, Phase 1 | 9967 | | | | 45 | | Antimetabolites, Antineoplastic | | Phase 3, Phase 2, Phase 1 | 7361 | | | | 46 | | Angiogenesis Modulating Agents | | Phase 3, Phase 2, Phase 1 | 4185 | | | | 47 | | Antimetabolites | | Phase 3, Phase 2, Phase 1 | 12054 | | | | 48 | | Albumin-Bound Paclitaxel | | Phase 3, Phase 2, Phase 1 | 2864 | | | | 49 | | Antimitotic Agents | | Phase 3, Phase 2, Phase 1 | 5657 | | | | 50 | | Etoposide phosphate | | Phase 3, Phase 2, Phase 1 | 1269 | | |
Interventional clinical trials: (show top 50)
(show all 157)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas | Unknown status | NCT00162721 | Phase 3 | | 2 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | Unknown status | NCT00954174 | Phase 3 | | 3 | Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer | Unknown status | NCT01087268 | Phase 3 | | 4 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma | Unknown status | NCT00020566 | Phase 3 | | 5 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | Unknown status | NCT00346164 | Phase 3 | | 6 | Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus | Completed | NCT00002706 | Phase 3 | | 7 | Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus | Completed | NCT00002459 | Phase 3 | | 8 | Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus | Completed | NCT00003128 | Phase 3 | | 9 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | Completed | NCT01012297 | Phase 3 | | 10 | Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus | Completed | NCT00002546 | Phase 3 | | 11 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | Completed | NCT00538850 | Phase 3 | | 12 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | Completed | NCT00002641 | Phase 3 | | 13 | E-MOSAIC Electronic Tool to Monitor Symptoms | Completed | NCT00477919 | Phase 3 | | 14 | Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma | Completed | NCT00003212 | Phase 3 | | 15 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | Completed | NCT00002764 | Phase 3 | | 16 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | Completed | NCT00716976 | Phase 3 | | 17 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | Recruiting | NCT01533207 | Phase 3 | | 18 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | Recruiting | NCT02180867 | Phase 2, Phase 3 | | 19 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Recruiting | NCT02306161 | Phase 3 | | 20 | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Recruiting | NCT01371981 | Phase 3 | | 21 | Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms | Active, not recruiting | NCT01376349 | Phase 3 | | 22 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | Active, not recruiting | NCT01231906 | Phase 3 | | 23 | High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma | Active, not recruiting | NCT00354744 | Phase 3 | | 24 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma | Active, not recruiting | NCT00354835 | Phase 3 | | 25 | Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma | Active, not recruiting | NCT00134030 | Phase 3 | | 26 | Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma | Active, not recruiting | NCT00075582 | Phase 3 | | 27 | Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer | Terminated | NCT01132547 | Phase 3 | | 28 | Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers | Unknown status | NCT02052128 | Phase 1, Phase 2 | | 29 | Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma | Unknown status | NCT00033709 | Phase 2 | | 30 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | Unknown status | NCT00410462 | Phase 2 | | 31 | Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma | Unknown status | NCT00003718 | Phase 2 | | 32 | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer | Unknown status | NCT00905658 | Phase 2 | | 33 | Chemotherapy in Treating Patients With Sarcoma of the Uterus | Completed | NCT00005643 | Phase 2 | | 34 | Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | Completed | NCT00025220 | Phase 2 | | 35 | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | Completed | NCT01637961 | Phase 2 | | 36 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | Completed | NCT01247571 | Phase 2 | | 37 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | Completed | NCT00031629 | Phase 2 | | 38 | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | Completed | NCT00114218 | Phase 2 | | 39 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | Completed | NCT00025506 | Phase 2 | | 40 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | Completed | NCT00378911 | Phase 2 | | 41 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | Completed | NCT00075400 | Phase 2 | | 42 | Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | Completed | NCT00815945 | Phase 2 | | 43 | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer | Completed | NCT00238121 | Phase 2 | | 44 | Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer | Completed | NCT00112489 | Phase 2 | | 45 | Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma | Completed | NCT00101127 | Phase 2 | | 46 | Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus | Completed | NCT00379145 | Phase 2 | | 47 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | Completed | NCT01154452 | Phase 1, Phase 2 | | 48 | Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma | Completed | NCT00003778 | Phase 2 | | 49 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | Completed | NCT00390234 | Phase 2 | | 50 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | Completed | NCT01553539 | Phase 2 |
|
